Skip to main content
Top
Gepubliceerd in: Quality of Life Research 4/2018

29-11-2017

Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases

Auteurs: Srinivas Raman, Keyue Ding, Edward Chow, Ralph M. Meyer, Yvette M. van der Linden, Daniel Roos, William F. Hartsell, Peter Hoskin, Jackson S. Y. Wu, Abdenour Nabid, Rick Haas, Ruud Wiggenraad, Scott Babington, William F. Demas, Carolyn F. Wilson, Rebecca K. S. Wong, Liting Zhu, Michael Brundage

Gepubliceerd in: Quality of Life Research | Uitgave 4/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

The EORTC QLQ-C30 and the Brief Pain Inventory (BPI) are validated tools for measuring quality of life (QOL) and the impact of pain in patients with advanced cancer. Interpretation of these instrument scores can be challenging and it is difficult to know what numerical changes translate to clinically significant impact in patients’ lives. To address this issue, our study sought to establish the minimal clinically important differences (MCID) for these two instruments in a prospective cohort of patients with advanced cancer and painful bone metastases.

Methods

Both anchor-based and distribution-based methods were used to estimate the MCID scores from patients enrolled in a randomized phase III trial evaluating two different re-irradiation treatment schedules. For the anchor-based method, the global QOL item from the QLQ-C30 was chosen as the anchor. Spearman correlation coefficients were calculated for all items and only those items with moderate or better correlation (|r| ≥ 0.30) with the anchor were used for subsequent analysis. A 10-point difference in the global QOL score was used to classify improvement and deterioration, and the MCID scores were calculated for each of these categories. These results were compared with scores obtained by the distribution-method, which estimates the MCID purely from the statistical characteristics of the sample population.

Results

A total of 375 patients were included in this study with documented pain responses and completed QOL questionnaires at 2 months. 9/14 items in the QLQ-C30 and 6/10 items in the BPI were found to have moderate or better correlation with the anchor. For deterioration, statistically significant MCID scores were found in all items of the QLQ-C30 and BPI. For improvement, statistically significant MCID scores were found in 7/9 items of the QLQ-C30 and 2/6 items of the BPI. The MCID scores for deterioration were uniformly higher than the MCIDs for improvement. Using the distribution-based method, there was good agreement between the 0.5 standard deviation (SD) values and anchor-based scores for deterioration. For improvement, there was less agreement and the anchor-based scores were lower than the 0.5 SD values obtained from the distribution-based method.

Conclusion

We present MCID scores for the QLQ-C30 and BPI instruments obtained from a large cohort of patients with advanced cancer undergoing re-irradiation for painful bone metastases. The results from this study were compared to other similar studies which showed larger MCID scores for improvement compared to deterioration. We hypothesize that disease trajectory and patient expectations are important factors in understanding the contrasting results. The results of this study can guide clinicians and researchers in the interpretation of these instruments.
Literatuur
1.
go back to reference Coleman, R. E. (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research, 12(20), 6243s–9s.CrossRef Coleman, R. E. (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research, 12(20), 6243s–9s.CrossRef
2.
go back to reference Chow, E., Zeng, L., Salvo, N., Dennis, K., Tsao, M., & Lutz, S. (2012). Update on the systematic review of palliative radiotherapy trials for bone metastases. Clinical Oncology, 24(2), 112–124.CrossRefPubMed Chow, E., Zeng, L., Salvo, N., Dennis, K., Tsao, M., & Lutz, S. (2012). Update on the systematic review of palliative radiotherapy trials for bone metastases. Clinical Oncology, 24(2), 112–124.CrossRefPubMed
3.
go back to reference Wong, E., Hoskin, P., Bedard, G., Poon, M., Zeng, L., Lam, H., Vulpe, H., Tsao, M., Pulenzas, N., & Chow, E. (2014). Re-irradiation for painful bone metastases—a systematic review. Radiotherapy and Oncology, 110(1), 61–70.CrossRefPubMed Wong, E., Hoskin, P., Bedard, G., Poon, M., Zeng, L., Lam, H., Vulpe, H., Tsao, M., Pulenzas, N., & Chow, E. (2014). Re-irradiation for painful bone metastases—a systematic review. Radiotherapy and Oncology, 110(1), 61–70.CrossRefPubMed
4.
go back to reference Chow, E., van der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S., Brundage, M. D., Nabid, A., Tissing-Tan, C. J., Oei, B., & Babington, S. (2014). Single versus multiple fractions of repeat radiation for painful bone metastases: A randomized, controlled, non-inferiority trial. The Lancet Oncology, 15(2), 164–171.CrossRefPubMed Chow, E., van der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S., Brundage, M. D., Nabid, A., Tissing-Tan, C. J., Oei, B., & Babington, S. (2014). Single versus multiple fractions of repeat radiation for painful bone metastases: A randomized, controlled, non-inferiority trial. The Lancet Oncology, 15(2), 164–171.CrossRefPubMed
5.
go back to reference Van den Beuken-van Everdingen, M. H., De Rijke, J. M., Kessels, A. G., Schouten, H. C., Van Kleef, M., & Patijn, J. (2007). Prevalence of pain in patients with cancer: A systematic review of the past 40 years. Annals of Oncology, 18(9), 1437–1449.CrossRefPubMed Van den Beuken-van Everdingen, M. H., De Rijke, J. M., Kessels, A. G., Schouten, H. C., Van Kleef, M., & Patijn, J. (2007). Prevalence of pain in patients with cancer: A systematic review of the past 40 years. Annals of Oncology, 18(9), 1437–1449.CrossRefPubMed
6.
go back to reference Teunissen, S. C., Wesker, W., Kruitwagen, C., de Haes, H. C., Voest, E. E., & de Graeff, A. (2007). Symptom prevalence in patients with incurable cancer: A systematic review. Journal of Pain and Symptom Management, 34(1), 94–104.CrossRefPubMed Teunissen, S. C., Wesker, W., Kruitwagen, C., de Haes, H. C., Voest, E. E., & de Graeff, A. (2007). Symptom prevalence in patients with incurable cancer: A systematic review. Journal of Pain and Symptom Management, 34(1), 94–104.CrossRefPubMed
7.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., de Haes, J. C., & Kaasa, S. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., de Haes, J. C., & Kaasa, S. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed
8.
go back to reference Fayers, P., & Bottomley, A. E. (2002). EORTC Quality of Life Group. Quality of life research within the EORTC—the EORTC QLQ-C30. European Journal of Cancer 38, 125–133.CrossRef Fayers, P., & Bottomley, A. E. (2002). EORTC Quality of Life Group. Quality of life research within the EORTC—the EORTC QLQ-C30. European Journal of Cancer 38, 125–133.CrossRef
10.
go back to reference Furler, L. (2013). Validity and reliability of the pain questionnaire” Brief Pain Inventory”. A literature research. Pflege Zeitschrift, 66(9), 546–550.PubMed Furler, L. (2013). Validity and reliability of the pain questionnaire” Brief Pain Inventory”. A literature research. Pflege Zeitschrift, 66(9), 546–550.PubMed
11.
go back to reference Chow, E., Wu, J. S., Hoskin, P., Coia, L. R., Bentzen, S. M., & Blitzer, P. H. (2002). International Bone Metastases Consensus Working Party. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiotherapy and Oncology 64(3):275–280.CrossRefPubMed Chow, E., Wu, J. S., Hoskin, P., Coia, L. R., Bentzen, S. M., & Blitzer, P. H. (2002). International Bone Metastases Consensus Working Party. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiotherapy and Oncology 64(3):275–280.CrossRefPubMed
12.
go back to reference Maringwa, J., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., Martinelli, F., Reeve, B. B., Gotay, C., Greimel, E., & Flechtner, H. (2011). Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Annals of Oncology, 15, 726. Maringwa, J., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., Martinelli, F., Reeve, B. B., Gotay, C., Greimel, E., & Flechtner, H. (2011). Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Annals of Oncology, 15, 726.
13.
go back to reference Maringwa, J. T., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., Martinelli, F., Vercauteren, J., Cleeland, C. S., Flechtner, H., & Gotay, C. (2011). Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Supportive Care in Cancer, 19(11), 1753–1760.CrossRefPubMed Maringwa, J. T., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., Martinelli, F., Vercauteren, J., Cleeland, C. S., Flechtner, H., & Gotay, C. (2011). Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Supportive Care in Cancer, 19(11), 1753–1760.CrossRefPubMed
14.
go back to reference Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61(2), 102–109.CrossRefPubMed Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61(2), 102–109.CrossRefPubMed
15.
go back to reference Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–144.CrossRefPubMed Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–144.CrossRefPubMed
16.
go back to reference Redelmeier, D. A., & Lorig, K. (1993). Assessing the clinical importance of symptomatic improvements: an illustration in rheumatology. Archives of Internal Medicine, 153(11), 1337–1342.CrossRefPubMed Redelmeier, D. A., & Lorig, K. (1993). Assessing the clinical importance of symptomatic improvements: an illustration in rheumatology. Archives of Internal Medicine, 153(11), 1337–1342.CrossRefPubMed
17.
go back to reference King, M. T. (1996). The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of Life Research, 5(6), 555–567.CrossRefPubMed King, M. T. (1996). The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of Life Research, 5(6), 555–567.CrossRefPubMed
18.
go back to reference Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal of Clinical Epidemiology, 56(5), 395–407.CrossRefPubMed Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal of Clinical Epidemiology, 56(5), 395–407.CrossRefPubMed
19.
go back to reference Wong, E., Zhang, L., Kerba, M., Arnalot, P. F., Danielson, B., Tsao, M., Bedard, G., Thavarajah, N., Cheon, P., Danjoux, C., & Pulenzas, N. (2015). Minimal clinically important differences in the EORTC QLQ-BN20 in patients with brain metastases. Supportive Care in Cancer, 23(9), 2731–2737.CrossRefPubMed Wong, E., Zhang, L., Kerba, M., Arnalot, P. F., Danielson, B., Tsao, M., Bedard, G., Thavarajah, N., Cheon, P., Danjoux, C., & Pulenzas, N. (2015). Minimal clinically important differences in the EORTC QLQ-BN20 in patients with brain metastases. Supportive Care in Cancer, 23(9), 2731–2737.CrossRefPubMed
20.
go back to reference Raman, S., Ding, K., Chow, E., Meyer, R. M., Nabid, A., Chabot, P., Coulombe, G., Ahmed, S., Kuk, J., Dar, A. R., & Mahmud, A. (2016). Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy. Quality of Life Research, 25(10), 2535–2541.CrossRefPubMed Raman, S., Ding, K., Chow, E., Meyer, R. M., Nabid, A., Chabot, P., Coulombe, G., Ahmed, S., Kuk, J., Dar, A. R., & Mahmud, A. (2016). Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy. Quality of Life Research, 25(10), 2535–2541.CrossRefPubMed
21.
go back to reference Wong, K., Zeng, L., Zhang, L., Bedard, G., Wong, E., Tsao, M., Barnes, E., Danjoux, C., Sahgal, A., Holden, L., & Lauzon, N. (2013). Minimal clinically important differences in the brief pain inventory in patients with bone metastases. Supportive Care in Cancer, 21(7), 1893–1899.CrossRefPubMed Wong, K., Zeng, L., Zhang, L., Bedard, G., Wong, E., Tsao, M., Barnes, E., Danjoux, C., Sahgal, A., Holden, L., & Lauzon, N. (2013). Minimal clinically important differences in the brief pain inventory in patients with bone metastases. Supportive Care in Cancer, 21(7), 1893–1899.CrossRefPubMed
22.
go back to reference Zeng, L., Chow, E., Zhang, L., Tseng, L. M., Hou, M. F., Fairchild, A., Vassiliou, V., Jesus-Garcia, R., El-Din, M. A., Kumar, A., & Forges, F. (2012). An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases. Supportive Care in Cancer, 20(12), 3307–3313.CrossRefPubMed Zeng, L., Chow, E., Zhang, L., Tseng, L. M., Hou, M. F., Fairchild, A., Vassiliou, V., Jesus-Garcia, R., El-Din, M. A., Kumar, A., & Forges, F. (2012). An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases. Supportive Care in Cancer, 20(12), 3307–3313.CrossRefPubMed
23.
go back to reference Bedard, G., Zeng, L., Zhang, L., Lauzon, N., Holden, L., Tsao, M., Danjoux, C., Barnes, E., Sahgal, A., Poon, M., & Chow, E. (2013). Minimal clinically important differences in the Edmonton Symptom Assessment System in patients with advanced cancer. Journal of Pain and Symptom Management, 46(2), 192–200.CrossRefPubMed Bedard, G., Zeng, L., Zhang, L., Lauzon, N., Holden, L., Tsao, M., Danjoux, C., Barnes, E., Sahgal, A., Poon, M., & Chow, E. (2013). Minimal clinically important differences in the Edmonton Symptom Assessment System in patients with advanced cancer. Journal of Pain and Symptom Management, 46(2), 192–200.CrossRefPubMed
24.
go back to reference Groenvold, M., Petersen, M. A., Aaronson, N. K., Arraras, J. I., Blazeby, J. M., Bottomley, A., Fayers, P. M., de Graeff, A., Hammerlid, E., Kaasa, S., & Sprangers, M. A. (2006). The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. European Journal of Cancer, 42(1), 55–64.CrossRefPubMed Groenvold, M., Petersen, M. A., Aaronson, N. K., Arraras, J. I., Blazeby, J. M., Bottomley, A., Fayers, P. M., de Graeff, A., Hammerlid, E., Kaasa, S., & Sprangers, M. A. (2006). The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. European Journal of Cancer, 42(1), 55–64.CrossRefPubMed
25.
go back to reference Chow, E., Ding, K., Parulekar, W. R., Wong, R. K., Van Der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S., Nabid, A., & Leer, J. W. (2016). Predictive model for survival in patients having repeat radiation treatment for painful bone metastases. Radiotherapy and Oncology, 118(3), 5475–51.CrossRef Chow, E., Ding, K., Parulekar, W. R., Wong, R. K., Van Der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S., Nabid, A., & Leer, J. W. (2016). Predictive model for survival in patients having repeat radiation treatment for painful bone metastases. Radiotherapy and Oncology, 118(3), 5475–51.CrossRef
26.
go back to reference Schwartz, C. E., & Sprangers, M. A. (1999). Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Social Science & Medicine, 48(11), 1531–1548.CrossRef Schwartz, C. E., & Sprangers, M. A. (1999). Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Social Science & Medicine, 48(11), 1531–1548.CrossRef
27.
go back to reference Mitera, G., Zhang, L., Sahgal, A., Barnes, E., Tsao, M., Danjoux, C., Holden, L., & Chow, E. (2012). A survey of expectations and understanding of palliative radiotherapy from patients with advanced cancer. Clinical Oncology, 24(2), 134–138.CrossRefPubMed Mitera, G., Zhang, L., Sahgal, A., Barnes, E., Tsao, M., Danjoux, C., Holden, L., & Chow, E. (2012). A survey of expectations and understanding of palliative radiotherapy from patients with advanced cancer. Clinical Oncology, 24(2), 134–138.CrossRefPubMed
28.
go back to reference Chow, E., Meyer, R. M., Chen, B. E., van der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S., Nabid, A., Tissing-Tan, C. J., & Oei, B. (2014). Impact of reirradiation of painful osseous metastases on quality of life and function: a secondary analysis of the NCIC CTG SC. 20 randomized trial. Journal of Clinical Oncology, 32(34), 3867–3873.CrossRefPubMedPubMedCentral Chow, E., Meyer, R. M., Chen, B. E., van der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S., Nabid, A., Tissing-Tan, C. J., & Oei, B. (2014). Impact of reirradiation of painful osseous metastases on quality of life and function: a secondary analysis of the NCIC CTG SC. 20 randomized trial. Journal of Clinical Oncology, 32(34), 3867–3873.CrossRefPubMedPubMedCentral
Metagegevens
Titel
Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases
Auteurs
Srinivas Raman
Keyue Ding
Edward Chow
Ralph M. Meyer
Yvette M. van der Linden
Daniel Roos
William F. Hartsell
Peter Hoskin
Jackson S. Y. Wu
Abdenour Nabid
Rick Haas
Ruud Wiggenraad
Scott Babington
William F. Demas
Carolyn F. Wilson
Rebecca K. S. Wong
Liting Zhu
Michael Brundage
Publicatiedatum
29-11-2017
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 4/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1745-8

Andere artikelen Uitgave 4/2018

Quality of Life Research 4/2018 Naar de uitgave